Janssen Search
Search results
TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
May 31, 2023 United States Additional post-hoc clinical data will be presented from Phase 3 DISCOVER trials providing clinical insights on the importance of shared decision making to address patient-reported symptoms SPRING HOUSE, PENNSYLVANIA, May 31, ...
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
Jun 03, 2024 New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing 1 Separate analyses from the MajesTEC-1 and OPTec studies are the first to underscore the ...
U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Jan 19, 2024 United States BALVERSA ® is the First and Only Targeted Therapy for Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Susceptible Fibroblast Growth Factor Receptor Alterations Phase 3 THOR Study Showed a 36 Percent ...
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemother
Sep 06, 2023 United States MARIPOSA-2 is the first Phase 3 study to show statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the post-osimertinib setting MARIPOSA-2 is the second RYBREVANT ® Phase 3 study ...
Johnson & Johnson showcases innovation and leadership in rheumatology at EULAR 2024 Congress
Jun 07, 2024 30 abstracts highlight the company’s robust portfolio and commitment to improving outcomes for patients with immune-mediated diseases Features positive results from a Phase 2 study of nipocalimab in Sjögren’s disease as a late-breaking oral ...
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Jul 02, 2024 CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy RARITAN, N.J., (July 2, 2024) /PRNewswire/ – ...
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
Mar 22, 2024 United States OPSYNVI ® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical guideline recommendations for ...
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
Aug 10, 2023 United States Bispecific antibody targeting GPRC5D receptor showed an overall response rate of more than 70 percent with durable responses, including in patients previously treated with a bispecific antibody or CAR-T cell therapy HORSHAM, ...
CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
Jun 05, 2023 United States At 16-months median follow-up, CARVYKTI ® significantly improved progression-free survival compared to two standard treatment s [1] Data presented at the 2023 ASCO and EHA Annual Meetings and published in The New England Journal ...
New Real-World Data Show TREMFYA® (guselkumab) Was Associated With Clinically Meaningful Improvements in Patient-Reported Outcomes for Adults Living With Active Psoriatic Arthritis
Nov 08, 2023 United States People living with treatment-resistant active psoriatic arthritis reported meaningful improvements in pain, physical function and fatigue on TREMFYA through six months Additional pooled data from three clinical trials support ...